No. (if known): 10/021,509

Attorney Docket No.: HO-P02046US1

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. ER 147056328 US in an envelope addressed to:

> MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	August 30, 2004	
	Date	

Annette Devereux Typed or printed name of person signing Certificate

Each paper must have its own certificate of mailing, or this certificate must identify Note: each submitted paper.

IDS (Citation) by Applicant

08-31.04

PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number.

Application Number the Paperwork Reduction Act of 1995, no persons are required to resp

## **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

porta to a concentration anormation	Turicas it displays a valid Civib control named
Application Number	10/021,509
Filing Date	December 7, 2001
First Named Inventor	Marie-Claude Gingras
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	HO-P02046US1

ENCLOSURES (Check all that apply)						
Fee Transr	mittal Form	Drawing(s)	After Allowance communication to Technology Center (TC)			
Fee Attached		Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendmer	nt/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
After	Final	Petition to Convert to a Provisional Application	Proprietary Information			
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter			
Extension	of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):			
Express At	pandonment Request	Request for Refund	Return Receipt Postcard 7 References			
x Information	Disclosure Statement	CD, Number of CD(s)				
Certified Control Document	opy of Priority					
Response	to Missing Parts/ Application	Remarks				
	onse to Missing Parts					
unde	r 37 CFR 1.52 or 1.53					
<u> </u>	SIGNAT	URE OF APPLICANT, ATTORNEY, OF	RAGENT			
Firm or Individual name	Melissa W. Arneta - 45.872					
Signature C	Signature					
Date August 30, 2004						

Tr	ar	15	n	ıi	tta	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147056328 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 30, 2004

Docket No.: HO-P02046US1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Marie-Claude Gingras et al.

Application No.: 10/021,509

Confirmation No.:

Filed: December 7, 2001

Art Unit: N/A

For:

TREM-1 SPLICE VARIANT FOR USE AND

MODIFYING IMMUNE RESPONSES

Examiner: Not Yet Assigned

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of these documents accompany this statement.

Applicant(s) have become aware of the following documents, cited in an International Search Report issued <u>July 1, 2004</u>, during the prosecution of international application no. EP01994219, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the International Search Report and each document cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

Application No.: 10/021,509 Docket No.: HO-P02046US1

The undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02046US1. A duplicate copy of this paper is enclosed.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. HO-P02046US1 from which the undersigned is authorized to draw.

Dated: August 30, 2004

Respectfully, submitted,

Melissa W. Aeosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)



PTO/SB/08A (10-01) Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
000	Suitate for form 1445/01 10			Application Number	10/021,509	-
١N	<b>VEORMATION</b>	اD ا	SCLOSURE	Filing Date	December 7, 2001	
S	TATEMENT I	BY /	APPLICANT	First Named Inventor	Marie-Claude Gingras	
				Art Unit	N/A	
(use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	HO-P02046US1	``

U.S. PATENT DOCUMENTS						
vant	Pages, Columns, Lii Where Relevant	Name of Patentee or Applicant	Publication Date	Document Number	Cite	Examiner
	Passages or Releva Figures Appear	of Cited Document	MM-DD-YYYY	Number-Kind Code <sup>2</sup> (if known)	No. <sup>1</sup>	Initials*
×	Figures App			Mariber Mila Gode (#Milann)	140.	IIIIdaio

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>A</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Тв	
	BA	WO-9906557	02-11-1999	Schering Corporation			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	CA	European Search Report Application No. 01994219				
	СВ	Lanier et al, "The IT AM-bearing transmembrane adator DAP 12 in lymphoid and myeloid cell function," Immunology Today: Viewpoint Vol. 21 No. 12, December 2000, pgs. 611 - 614.				
	СС	Dietrich et al, "Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells," Microbes and Infection 2000, pgs. 323-329.				
	CD	Bouchan et al, "TREM-1 amplifies inflammation and is a criucial mediator of septic shock," Nature Vol. 410, April 26, 2001, pgs. 1103 - 1107.				
	CE	Nochi et al, "Modulation of Hepatic Granulomatous Responses by Transgene Expression of DAP 12 or TREM-1-Ig Molecules," American Journal of Pathology Vol. 162, No. 4, April 2003, pgs. 1191 - 1201.				
	CF	Wilson et al, "DAP 12 and KAP10 (DAP10)-Novel Transmembrane Adaptor Proteins of the CD3 Family," Immunologic Research 22/1, 2000, pgs 21-42.				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	_	Date	
Signature		 Considered	

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.